U K
B U S I N E S S
P A R K
home page

The information below comes from the UK Activity Report.
Click here for further details

Vanguard Medica Vanguard Medica is forming an alliance with Menarini of Italy to distribute its frovatriptin migraine treatment in Europe. 14-Sep-1999 Vanguard Medica has reached agreement with 3M Pharmaceuticals to develop an oral treatment for liver infection caused by hepatitis C, but has abandoned the development of a treatment for kidney failure. 10-Dec-1998 Vanguard Medica has awarded North American distribution rights for its frovatriptan migraine drug to Elan of Ireland. 10-Oct-1998 Vanguard Medica has reached agreement with Roche for the development of the VML588 treatment for kidney failure and brain haemorrhage. 08-Sep-1998 SmithKline Beecham has decided not to proceed with plans to sell a new migraine treatment that has been developed by Vanguard Medica, and Vanguard is now looking for another marketing partner for the drug. 14-May-1998 Vanguard Medica has awarded European and Latin American marketing rights for its VML 262 treatment for psoriasis to Stiefel Laboratories of the US, and is planning to sign a partner for the US market after phase II trials in the autumn. 17-Mar-1998 Vanguard Medica, the biotechnology company, is to raise £26m in a share placing in order to finance the development of migraine and asthma drugs. 13-Nov-1997 Vanguard Medica has licensed VML252, a drug for patients with kidney disease, to Sankyo of Japan, and the deal is expected to bring in up to $10m. 11-Oct-1997 Vanguard Medica is dropping a new treatment for ulcerative colitis due to insufficient efficacy, but expects to seek approval for a new migraine treatment later this year. 24-Sep-1997 Vanguard Medica is to start the final stage of clinical testing for VML251, its migraine drug, and hopes to launch the product in 2000. 19-Nov-1996 Vanguard Medica, the drug development concern, is to start developing compounds under licence for biotechnology companies. 06-Sep-1996 Vanguard Medica, the pharmaceutical development company, is to float with a value of £111m. 03-May-1996 Vanguard Medica, the pharmaceutical development company, plans to raise about £30m in a flotation in May. 20-Mar-1996 The information above comes from the UK Activity Report Copyright UK Business Park 1995-2007